October 20, 2025
Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions
Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and…
Read more
September 17, 2025
Contera Pharma announces positive topline results in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Hørsholm, September 17, 2025 - Contera Pharma A/S, a clinical-stage…
Read more
August 28, 2025
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease
Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage…
Read more